US 11,958,896 B2
Antibodies recognizing tau
Robin Barbour, Walnut Creek, CA (US); Svetlana Alexander, Sunnyvale, CA (US); Mark Renz, Millbrae, CA (US); Shuning Gai, Mountain View, CA (US); Tarlochan S. Nijjar, Orinda, CA (US); Philip James Dolan, III, Forster City, CA (US); and Philip Payne, Turlock, CA (US)
Assigned to Prothena Biosciences Limited, Dublin (IE)
Appl. No. 16/500,251
Filed by Prothena Biosciences Limited, Dublin (IE)
PCT Filed May 2, 2018, PCT No. PCT/US2018/030739
§ 371(c)(1), (2) Date Oct. 2, 2019,
PCT Pub. No. WO2018/204546, PCT Pub. Date Nov. 8, 2018.
Claims priority of provisional application 62/580,408, filed on Nov. 1, 2017.
Claims priority of provisional application 62/500,427, filed on May 2, 2017.
Prior Publication US 2022/0089702 A1, Mar. 24, 2022
Int. Cl. C07K 16/18 (2006.01)
CPC C07K 16/18 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
OG exemplary drawing
 
1. An antibody that binds human tau, comprising three heavy chain CDRs and three light chain CDRs of a mouse antibody characterized by a heavy chain variable region having an amino acid sequence comprising SEQ ID NO: 7 and a light chain variable region having an amino acid sequence comprising SEQ ID NO:8.